• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BRAF V600E 突变型肺腺癌对达拉非尼和曲美替尼的快速且显著反应

Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.

作者信息

Ota Takayo, Okabayashi Aya, Fukuoka Masahiro

机构信息

Department of Medical Oncology Izumi City General Hospital Izumi Japan.

Department of Dermatology Izumi City General Hospital Izumi Japan.

出版信息

Respirol Case Rep. 2021 Aug 30;9(10):e0841. doi: 10.1002/rcr2.841. eCollection 2021 Oct.

DOI:10.1002/rcr2.841
PMID:34484797
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8403980/
Abstract

V-raf murine sarcoma viral oncogene homologue B1 (BRAF) is a proto-oncogene that regulates cell proliferation and survival. BRAF V600E-mutated lung cancer has aggressive characteristics and is resistant to chemotherapies. Combination of BRAF-specific inhibitor dabrafenib and mitogen-activated protein kinase kinase (MEK) inhibitor trametinib is the standard treatment for BRAF V600E-mutated lung cancer. We report a case of BRAF V600E-mutated lung adenocarcinoma, which presented with respiratory distress due to deterioration of advanced cancer. The tumour responded rapidly and significantly to BRAF/MEK inhibitors, and the patient's symptoms improved within 2 weeks. BRAF/MEK inhibitors are effective treatment in BRAF-mutated lung cancer even under critical conditions.

摘要

V-raf鼠肉瘤病毒癌基因同源物B1（BRAF）是一种调节细胞增殖和存活的原癌基因。BRAF V600E突变型肺癌具有侵袭性特征，并且对化疗耐药。BRAF特异性抑制剂达拉非尼和丝裂原活化蛋白激酶激酶（MEK）抑制剂曲美替尼联合使用是BRAF V600E突变型肺癌的标准治疗方法。我们报告了一例BRAF V600E突变型肺腺癌病例，该病例因晚期癌症病情恶化出现呼吸窘迫。肿瘤对BRAF/MEK抑制剂迅速且显著地产生反应，患者症状在2周内得到改善。即使在危急情况下，BRAF/MEK抑制剂对BRAF突变型肺癌也是有效的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25e6/8403980/bd81c4447ce0/RCR2-9-e0841-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25e6/8403980/bd81c4447ce0/RCR2-9-e0841-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25e6/8403980/bd81c4447ce0/RCR2-9-e0841-g001.jpg

相似文献

1
Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.BRAF V600E 突变型肺腺癌对达拉非尼和曲美替尼的快速且显著反应
Respirol Case Rep. 2021 Aug 30;9(10):e0841. doi: 10.1002/rcr2.841. eCollection 2021 Oct.
2
Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF-mutated poorly differentiated thyroid cancer: A case report and review of the literature.达拉非尼联合曲美替尼治疗转移性 BRAF 突变低分化甲状腺癌相关间质性肺病：病例报告及文献复习。
Int J Clin Pharmacol Ther. 2022 May;60(5):225-231. doi: 10.5414/CP204184.
3
Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression.病例报告：多线治疗进展后，使用达拉非尼和曲美替尼联合治疗携带BRCA2胚系突变的BRAF V600E突变型肺腺癌
Front Oncol. 2024 Apr 23;14:1387388. doi: 10.3389/fonc.2024.1387388. eCollection 2024.
4
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.达拉非尼联合或不联合维莫非尼治疗BRAF突变的非小细胞肺癌。
PLoS One. 2015 Feb 23;10(2):e0118210. doi: 10.1371/journal.pone.0118210. eCollection 2015.
5
Successful re-challenge of dabrafenib-trametinib combination therapy in advanced -mutant non-small cell lung cancer after previous cytotoxic chemotherapy, targeted therapy, and immunotherapy: a case report.先前接受细胞毒性化疗、靶向治疗和免疫治疗后，达拉非尼-曲美替尼联合疗法在晚期BRAF突变型非小细胞肺癌中的成功再挑战：一例报告
Ann Transl Med. 2022 Sep;10(18):1029. doi: 10.21037/atm-22-3887.
6
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF non-small cell lung cancer.BRAF 非小细胞肺癌中 BRAF 和 MEK 抑制剂耐药的分子机制。
Eur J Cancer. 2020 Jun;132:211-223. doi: 10.1016/j.ejca.2020.03.025. Epub 2020 May 6.
7
Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring V600E Mutation.达拉非尼联合曲美替尼对一名患有V600E突变的非小细胞肺癌腹膜转移癌患者疗效显著。
Onco Targets Ther. 2022 Nov 11;15:1369-1374. doi: 10.2147/OTT.S375246. eCollection 2022.
8
Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in V600E-mutated lung cancer.细胞周期蛋白依赖性激酶4上调介导V600E突变型肺癌对达拉非尼加曲美替尼的获得性耐药。
Transl Lung Cancer Res. 2021 Sep;10(9):3737-3744. doi: 10.21037/tlcr-21-415.
9
Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.达拉非尼和曲美替尼对一名BRAF V600E突变且微卫星高度不稳定（MSI-H）的转移性子宫内膜癌患者的疗效
Exp Hematol Oncol. 2017 Jan 10;6:1. doi: 10.1186/s40164-016-0061-2. eCollection 2017.
10
EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF mutation: a case report and review of literature.EGFR/BRAF/MEK联合抑制治疗获得性BRAF突变的EGFR突变型肺腺癌患者：一例报告及文献复习
Cancer Drug Resist. 2021 Dec 1;4(4):1019-1027. doi: 10.20517/cdr.2021.98. eCollection 2021.

引用本文的文献

1
Exploring cellular plasticity and resistance mechanisms in lung cancer: Innovations and emerging therapies.探索肺癌中的细胞可塑性和耐药机制：创新与新兴疗法
J Pharm Anal. 2025 May;15(5):101179. doi: 10.1016/j.jpha.2024.101179. Epub 2025 Jan 3.
2
Lung cancer: Animal model of lung cancer, molecular carcinogenesis of lung cancer, and antitumor effect of against lung cancer.肺癌：肺癌动物模型、肺癌的分子致癌作用以及（某种物质）对肺癌的抗肿瘤作用。 （这里原文“against lung cancer”前缺少关键信息，推测可能是某种物质或治疗手段等，翻译只能按现有内容尽量准确呈现）
Open Vet J. 2025 Feb;15(2):482-503. doi: 10.5455/OVJ.2025.v15.i2.1. Epub 2025 Feb 28.
3

本文引用的文献

1
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.BRAF 在非小细胞肺癌（NSCLC）中的作用：又一阻碍。
Cancer Treat Rev. 2018 May;66:82-94. doi: 10.1016/j.ctrv.2018.04.006. Epub 2018 Apr 24.
2
Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.BRAF V600E/丝裂原活化蛋白激酶途径通过FOS/GABP对人类癌症中突变型端粒酶逆转录酶的调控
Nat Commun. 2018 Feb 8;9(1):579. doi: 10.1038/s41467-018-03033-1.
3
Mutation of the TERT promoter leads to poor prognosis of patients with non-small cell lung cancer.
PD-L1-negative non-small cell lung cancer harbouring a rare mutation with successful treatment of first-line pembrolizumab plus chemotherapy: A case report and review the literature.
携带罕见突变的程序性死亡配体1（PD-L1）阴性非小细胞肺癌经一线帕博利珠单抗联合化疗成功治疗：一例报告并文献复习
Respirol Case Rep. 2023 May 3;11(6):e01155. doi: 10.1002/rcr2.1155. eCollection 2023 Jun.
4
In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation.阿帕替尼抗非小细胞肺癌活性的体外和体内分析：重新发现新的药物靶点V600E突变
Cancer Cell Int. 2023 Feb 9;23(1):21. doi: 10.1186/s12935-022-02723-7.
端粒酶逆转录酶（TERT）启动子突变导致非小细胞肺癌患者预后不良。
Oncol Lett. 2017 Aug;14(2):1609-1614. doi: 10.3892/ol.2017.6284. Epub 2017 May 31.
4
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.达拉非尼用于BRAF（V600E）阳性晚期非小细胞肺癌患者：一项单臂、多中心、开放标签的2期试验。
Lancet Oncol. 2016 May;17(5):642-50. doi: 10.1016/S1470-2045(16)00077-2. Epub 2016 Apr 11.
5
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.非小细胞肺癌中 BRAF 突变相关的临床、病理和生物学特征。
Clin Cancer Res. 2013 Aug 15;19(16):4532-40. doi: 10.1158/1078-0432.CCR-13-0657. Epub 2013 Jul 5.